Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.

Scheduling is based on the expected MA date unless a delay is requested and agreed. We aim to align the committee meeting with the MA date to publish final guidance within 90 days of receiving MA. The ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A new draft guideline published today aims to address this widespread variation by recommending a standardised approach to rehabilitation across five major neurological conditions, including brain and ...

For further information on how we select topics for development, please see our page about topic selection ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The topic overview describes the core elements to be covered. It also lists the key guidance sources that will be used to underpin the quality statements. The quality standards advisory committee ...

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] Draft guidance Technology appraisal guidance 29 ...